Skip to main content

Marker Therapeutics, Inc. (MRKR)

NASDAQ: MRKR · IEX Real-Time Price · USD
1.45
+0.01 (0.69%)
After-hours:Oct 22, 2021 7:31 PM EDT
1.44
-0.10 (-6.49%)
At close: Oct 22, 4:00 PM
Market Cap119.63M
Revenue (ttm)n/a
Net Income (ttm)-35.56M
Shares Out83.03M
EPS (ttm)-0.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume540,335
Open1.53
Previous Close1.54
Day's Range1.43 - 1.53
52-Week Range1.32 - 3.77
Beta1.30
AnalystsBuy
Price Target6.38 (+343.1%)
Est. Earnings DateNov 9, 2021

About MRKR

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment...

IndustryBiotechnology
CEOPeter Hoang
Employees44
Stock ExchangeNASDAQ
Ticker SymbolMRKR
Full Company Profile

Financial Performance

In 2020, MRKR's revenue was $466,785, an increase of 118.95% compared to the previous year's $213,194. Losses were -$28.71 million, 34.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for MRKR stock is "Buy." The 12-month stock price forecast is 6.38, which is an increase of 343.06% from the latest price.

Price Target
$6.38
(343.06% upside)
Analyst Consensus: Buy

News

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

HOUSTON, Sept. 7, 2021 /PRNewswire/ --  Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

1 month ago - PRNewsWire

Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial

Marker Therapeutics Inc (NASDAQ: MRKR) received notice of a Product Development Research award of approximately $13.1 million from Texas's Cancer Prevention and Research Institute (CPRIT). The CPRIT awa...

2 months ago - Benzinga

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

HOUSTON, Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

2 months ago - PRNewsWire

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

HOUSTON, Aug. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

2 months ago - PRNewsWire

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

HOUSTON, July 28, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

2 months ago - PRNewsWire

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML

HOUSTON, July 6, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies fo...

3 months ago - PRNewsWire

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

4 months ago - PRNewsWire

5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to...

Other symbols:ITRMSESNTELLVTGN
5 months ago - PennyStocks

Top Penny Stocks to Buy Today? Here's 3 to Watch in 2021

Top penny stocks to buy today? Check these 3 out for your watchlist The post Top Penny Stocks to Buy Today?

Other symbols:CSCW
5 months ago - PennyStocks

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

HOUSTON, May 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies fo...

5 months ago - PRNewsWire

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesd...

HOUSTON, April 29, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

5 months ago - PRNewsWire

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at t...

HOUSTON, April 27, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

5 months ago - PRNewsWire

Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't?

Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

10 Reddit Penny Stocks Seeing the Most Chatter Today

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on...

7 months ago - InvestorPlace

Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday

Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut S...

Other symbols:DYAIODT
7 months ago - Benzinga

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...

7 months ago - Benzinga

Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday

Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis ...

Other symbols:ALECCLVS
7 months ago - Benzinga

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

HOUSTON, March 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

7 months ago - PRNewsWire

Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference

HOUSTON, March 15, 2021 /PRNewswire/ --  Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapie...

7 months ago - PRNewsWire

Marker Therapeutics Stock Plunges On Capital Raise At 31% Discount

Marker Therapeutics Inc (NASDAQ: MRKR) priced an underwritten public offering of 28.57 million common shares at $1.75 per share, representing a 31% discount from the last close price of $2.53 on Thursda...

7 months ago - Benzinga

Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

HOUSTON, March 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

7 months ago - PRNewsWire

Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

HOUSTON, March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

7 months ago - PRNewsWire

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results

HOUSTON, March 9, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

7 months ago - PRNewsWire

Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Sp...

HOUSTON, Jan. 13, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

9 months ago - PRNewsWire

Why Cyclo, Vivos Therapeutics And More Are Moving Today

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Dise...

Other symbols:VVOSTHCCYTH
9 months ago - Benzinga